Concepedia

Author

Parvis Sadjadian

Johannes Wesling Klinikum MindenORCID

Also Known As

Evangelos Bournakis, Florian H. Heidel, P Sadjadian, P. Sadjadian, Parvis Sadjadian

44

Publications

908

Citations

15

H-Index

6

Concepts

All Affiliations

Johannes Wesling Klinikum MindenBielefeld UniversityHelmholtz Zentrum MünchenInsermGerman Center for Lung Research
PS

About

Parvis Sadjadian is an author at Johannes Wesling Klinikum Minden specializing in hematology, medicine, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

195

2

Hematology

2

2

195

3

Pathology

1

1

31

4

Oncology

1

1

31

5

Pharmacotherapy

1

1

164

Parvis Sadjadian

×

14

Publications

671

Citations

12

H-Index

YearCitations

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi,

The Lancet

2023

164

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon <i>EGFR</i> Mutations Pretreated With Reversible EGFR Inhibitors

David F. Heigener, Christian Schumann, Martin Sebastian,

The Oncologist

2015

87

Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)

Frank Griesinger, Wilfried Eberhardt, Arnd Nusch,

Lung Cancer

2020

83

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study

Michael Thomas, Santiago Ponce-Aix, Alejandro Navarro,

Annals of Oncology

2018

80

A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer

Michael Thomas, Parvis Sadjadian, Jens Kollmeier,

Investigational New Drugs

2017

50

Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs

Marta Sobas, Jean‐Jacques Kiladjian, Yan Beauverd,

Blood Advances

2022

41

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms

Valerio De Stefano, Alessandra Carobbio, Vincenzo Di Lazzaro,

Blood Cancer Journal

2018

37

High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation

Kai Wille, Parvis Sadjadian, Tatjana Becker,

Annals of Hematology

2018

31

Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms

Karlo Huenerbein, Parvis Sadjadian, Tatjana Becker,

Annals of Hematology

2020

26

Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies

Rohit Sekhri, Parvis Sadjadian, Tatjana Becker,

Annals of Hematology

2021

21

Page 1